David Meek, Mirati Therapeutics CEO (Photographer: Marlene Awaad/Bloomberg via Getty Images)
September 7, 2022 06:05 PM EDTUpdated September 8, 03:03 PM
R&D

#ES­MO22: Mi­rati vs. Am­gen: Scrap­py KRAS G12C con­tender out­per­forms its gi­ant ri­val in col­orec­tal can­cer

John Carroll

Editor & Founder

PARIS — This week­end at ES­MO, the KRAS bat­tle be­tween Am­gen and its pesky biotech ri­vals at Mi­rati will con­tin­ue with new slices of com­bo da­ta …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mod­er­na re­ports slow start to RSV sales as Ban­cel steps back from com­mer­cial role

Sarep­ta dis­con­tin­ues work on next-gen ex­on-skip­ping drug for Duchenne

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

Q&A: Demis Has­s­abis talks win­ning the No­bel Prize, build­ing an AI biotech sans lab, and Trump’s po­ten­tial im­pact

GSK CEO Em­ma Walm­s­ley on the new Trump ad­min­is­tra­tion, trust, AI and Chi­na

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times